Adam Urato

Dr. Robert Chen, psychiatry researcher focused on biomarkers and therapeutics, and Dr. Adam Urato, maternal-fetal medicine physician and FDA panel expert, debate SSRI use in pregnancy. They tackle serotonin’s role in fetal brain development, how SSRIs cross the placenta, limits of the evidence, newborn risks, informed consent failures, and the need for clearer patient conversations.

Dr. Adam Urato, Chief of Maternal-Fetal Medicine at MetroWest Medical Center, dives deep into the troubling implications of medications during pregnancy. He discusses the risks associated with SSRIs and Tylenol, revealing research that links these drugs to developmental issues in children. Urato advocates for clearer FDA warnings, emphasizing the importance of informed decision-making for expectant mothers. He also explores the implications of medications like Adderall and highlights the need for better medication management before conception, urging more transparency in pharmaceutical messaging.

In this discussion, Dr. Adam Urato, a maternal-fetal medicine specialist, highlights the critical lack of informed consent regarding SSRI antidepressants during pregnancy. He explains how serotonin affects fetal development and the potential negative impacts of SSRIs on unborn children. The conversation also addresses the rise in medical interventions in pregnancy and questions whether the pharmaceutical industry contributes to doctors' indifference about these risks. Dr. Urato advocates for more compassionate care and awareness for expectant mothers facing mental health challenges.